Replies to post #246944 on Biotech Values

[rfj1862]

Judging from the interest on twitter- I expect the immediate reaction for VKTX will be amplified in both directions. If the 12-week results for VK2809 are unexpectedly bad, maybe the stock goes to single digits on the PPS for a short time but I think it recovers and ends up in the mid teens.

I would love to see $30s but I'm wondering if interest in VKTX is saturated (looking at Twitter) and people are looking for a reason to sell the news.

Then again we live in a bubble of very well-informed people and just because it seems to us like everyone knows about it, in reality probably 99.9% of people haven't heard of the name.

[jbog]

better than Madrigal's resmetirom, OR equal to resmetirom with a better safety profile,

Alt had some very nice results but because Madrigal set the bar with biopsy confirmation the street didn't seem to care.

Good Luck